Department of Microbiology and Immunology, Faculty of Pharmacy, Alexandria University, Egypt; Current affiliation: Department of Immunology, University Medicine Greifswald, Greifswald, Germany.
Pathogen Molecular Genetics Section, Laboratory of Bacteriology, National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, MD, USA.
Trends Microbiol. 2019 Apr;27(4):303-322. doi: 10.1016/j.tim.2018.12.009. Epub 2019 Jan 19.
Staphylococcus aureus (S. aureus) is a notorious pathogen and one of the most frequent causes of biofilm-related infections. The treatment of S. aureus biofilms is hampered by the ability of the biofilm structure to shield bacteria from antibiotics as well as the host's immune system. Therefore, new preventive and/or therapeutic interventions, including the use of antibody-based approaches, are urgently required. In this review, we describe the mechanisms by which anti-S. aureus antibodies can help in combating biofilms, including an up-to-date overview of monoclonal antibodies currently in clinical trials. Moreover, we highlight ongoing efforts in passive vaccination against S. aureus biofilm infections, with special emphasis on promising targets, and finally indicate the direction into which future research could be heading.
金黄色葡萄球菌（S. aureus）是一种臭名昭著的病原体，也是生物膜相关感染的最常见原因之一。生物膜结构能够保护细菌免受抗生素和宿主免疫系统的攻击，这使得金黄色葡萄球菌生物膜的治疗受到阻碍。因此，迫切需要新的预防和/或治疗干预措施，包括使用基于抗体的方法。在这篇综述中，我们描述了抗金黄色葡萄球菌抗体在对抗生物膜方面的作用机制，包括目前正在临床试验中的单克隆抗体的最新概述。此外，我们还强调了针对金黄色葡萄球菌生物膜感染的被动免疫接种的持续努力，特别强调了有前途的靶标，并最终指出了未来研究的方向。
